Histogenics Corporation to Ring the Nasdaq Stock Market Closing Bell
October 13 2016 - 8:30AM
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative
medicine company focused on developing and commercializing products
in the musculoskeletal space, will ring the Closing Bell at Nasdaq
today in celebration of its recently closed $30 million financing.
Histogenics President and CEO, Adam Gridley will be joined by
the Company’s executive team and colleagues for the Closing Bell
ceremony beginning at 3:45 pm ET.
A livestream of the Nasdaq Closing Bell will be
available from 3:45 to 4:00 p.m. EDT
at: https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx.
About Histogenics
Corporation
Histogenics is a leading regenerative medicine
company developing and commercializing products in the
musculoskeletal segment of the marketplace. Histogenics’
regenerative medicine platform combines expertise in cell
processing, scaffolding, tissue engineering, bioadhesives and
growth factors to provide solutions to treat
musculoskeletal-related conditions. Histogenics’ first
investigational product candidate, NeoCart®, is currently in Phase
3 clinical development. NeoCart is an autologous cell therapy
designed to treat cartilage defects in the knee using the patient’s
own cells. Knee cartilage defects represent a significant
opportunity in the United States, with an estimated 500,000 or more
applicable procedures each year. NeoCart is designed to
exhibit characteristics of articular, hyaline cartilage prior to
and upon implantation into the knee and therefore does not rely on
the body to make new cartilage, characteristics not exhibited in
other current treatment options. For more information, please
visit www.histogenics.com.
Contact:
Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Apr 2024 to May 2024
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From May 2023 to May 2024